Sterling Wu

697 total citations
10 papers, 215 citations indexed

About

Sterling Wu is a scholar working on Infectious Diseases, Virology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sterling Wu has authored 10 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 3 papers in Virology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sterling Wu's work include HIV/AIDS drug development and treatment (4 papers), HIV Research and Treatment (3 papers) and Renal cell carcinoma treatment (3 papers). Sterling Wu is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), HIV Research and Treatment (3 papers) and Renal cell carcinoma treatment (3 papers). Sterling Wu collaborates with scholars based in United States, United Kingdom and Belgium. Sterling Wu's co-authors include John E. Kraus, Tomoko Maeda‐Chubachi, Amy S. Paller, K. Thomas Robbins, Kelly Gallagher, Thomas Powles, Tom Waddell, Frédéric Pouliot, L. Rhoda Molife and Elizabeth R. Plimack and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Academy of Dermatology and The Oncologist.

In The Last Decade

Sterling Wu

10 papers receiving 205 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sterling Wu United States 4 113 75 42 31 30 10 215
Osmo Kari Finland 13 186 1.6× 218 2.9× 16 0.4× 60 1.9× 44 1.5× 27 483
Hanna Grindebacke Sweden 6 58 0.5× 104 1.4× 22 0.5× 147 4.7× 232 7.7× 7 374
Fanny Silviu-Dan Canada 8 112 1.0× 137 1.8× 26 0.6× 77 2.5× 43 1.4× 11 371
Ziyuan He United States 7 19 0.2× 51 0.7× 10 0.2× 37 1.2× 34 1.1× 12 169
Kirk Barber Canada 12 249 2.2× 75 1.0× 16 0.4× 17 0.5× 87 2.9× 27 337
Lilian F. de Ruiter Netherlands 8 23 0.2× 84 1.1× 5 0.1× 39 1.3× 91 3.0× 9 293
Bridget Kaufman United States 6 373 3.3× 177 2.4× 6 0.1× 77 2.5× 86 2.9× 15 445
Idit Lachover‐Roth Israel 8 85 0.8× 117 1.6× 26 0.6× 39 1.3× 29 1.0× 21 286
F. Tétart France 9 106 0.9× 38 0.5× 9 0.2× 15 0.5× 35 1.2× 48 285
Adam Russell‐Hallinan Ireland 9 79 0.7× 6 0.1× 10 0.2× 8 0.3× 22 0.7× 16 277

Countries citing papers authored by Sterling Wu

Since Specialization
Citations

This map shows the geographic impact of Sterling Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sterling Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sterling Wu more than expected).

Fields of papers citing papers by Sterling Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sterling Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sterling Wu. The network helps show where Sterling Wu may publish in the future.

Co-authorship network of co-authors of Sterling Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Sterling Wu. A scholar is included among the top collaborators of Sterling Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sterling Wu. Sterling Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Motzer, Robert J., David A. Braun, Thomas Powles, et al.. (2025). INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations
2.
Choueiri, Toni K., Thomas Powles, David A. Braun, et al.. (2024). 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist. 29(Supplement_1). S15–S15. 3 indexed citations
3.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2023). Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.. Journal of Clinical Oncology. 41(17_suppl). LBA4501–LBA4501. 45 indexed citations
4.
5.
Wu, Sterling, Feifan Zhang, David Dorey, et al.. (2020). 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Open Forum Infectious Diseases. 7(Supplement_1). S544–S544. 2 indexed citations
6.
Talarico, Christine L., Sterling Wu, Marty St. Clair, et al.. (2020). 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. Open Forum Infectious Diseases. 7(Supplement_1). S540–S541. 4 indexed citations
7.
D’Amico, Ronald, Paul Benn, Cynthia McCoig, et al.. (2020). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S847–S848. 2 indexed citations
8.
Paller, Amy S., Tomoko Maeda‐Chubachi, Sterling Wu, et al.. (2018). A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology. 80(1). 89–98.e3. 129 indexed citations
9.
Wu, Sterling, et al.. (2017). E-learning: less is more. BioTechniques. 26(4). 37–38. 1 indexed citations
10.
Klein, Nicola P., John Hansen, Edwin Lewis, et al.. (2010). Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization. The Pediatric Infectious Disease Journal. 29(7). 613–617. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Osmo Kari Breakdown of academic impact, for papers by Hanna Grindebacke Breakdown of academic impact, for papers by Fanny Silviu-Dan Breakdown of academic impact, for papers by Ziyuan He Breakdown of academic impact, for papers by Kirk Barber Breakdown of academic impact, for papers by Lilian F. de Ruiter Breakdown of academic impact, for papers by Bridget Kaufman Breakdown of academic impact, for papers by Idit Lachover‐Roth Breakdown of academic impact, for papers by F. Tétart Breakdown of academic impact, for papers by Adam Russell‐Hallinan
Rankless by CCL
2026